Colombia vs Libya: Cause of death, by non-communicable diseases, ages 5-14
Colombia
43.6%
in 2021
Libya
45.2%
in 2021
Colombia rank
68th
Libya rank
66th
Cause of death, by non-communicable diseases, ages 5-14 over time
- Colombia
- Libya
How they compare
Libya currently reports 45.2% against 43.6% in Colombia, a difference of 1.6%.
The two have swapped places 2 times across 6 shared years of data; in 2000 it was Libya ahead.
Colombia ranks 68th and Libya ranks 66th of 185 countries.
Across the 3 decades both report, Colombia averaged higher in 2 and Libya in 1.
Head to head by decade
| Decade | Colombia | Libya | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 30.4% | 44.1% | 13.8% | Libya |
| 2010s | 39.5% | 29.8% | 9.7% | Colombia |
| 2020s | 44.8% | 38.1% | 6.7% | Colombia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher cause of death, by non-communicable diseases, ages 5-14, Colombia or Libya?
- Libya, at 45.2% against 43.6% in Colombia as of 2021.
- What is the difference in cause of death, by non-communicable diseases, ages 5-14 between Colombia and Libya?
- 1.6%, with Libya ahead.
- How many years of comparable data are there for Colombia and Libya?
- 6 years are reported by both, from 2000 to 2021.
- How do Colombia and Libya rank globally for cause of death, by non-communicable diseases, ages 5-14?
- Colombia ranks 68th and Libya ranks 66th of 185 countries.
- Where does this data come from?
- Global Health Estimates, World Health Organization (WHO), published as Cause of death, by non-communicable diseases, ages 5-14 (% of total deaths ages 5-14). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths ages 5-14 due to non-communicable diseases divided by number of all deaths ages 5-14, expressed by percentage. Non-Communicable diseases include cancer, diabetes mellitus, cardiovascular diseases, digestive diseases, skin diseases, musculoskeletal diseases, and congenital anomalies.